[Retreatment with epidermal growth factor receptor inhibitor after initial failure in advanced non-small cell lung...

Area of Science:

• Oncology
• Medical Research
• Pharmacology

Background:

• Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used for chemorefractory non-small cell lung cancer (NSCLC).
• Limited treatment options exist for advanced NSCLC patients who fail initial EGFR-TKI therapy.
• This study investigates the efficacy of retreatment with EGFR-TKIs after initial treatment failure.

Purpose of the Study:

• To evaluate the effectiveness of retreatment with EGFR-TKIs in patients with advanced NSCLC who have progressed on prior EGFR-TKI therapy.
• To identify predictive factors for successful retreatment with EGFR-TKIs.

Main Methods:

• A retrospective study analyzed 71 patients with NSCLC who experienced treatment failure after initial EGFR-TKI therapy.
• Patients were retreated with EGFR-TKIs upon observed tumor progression.
• Univariate COX analysis was used to identify factors associated with progression-free survival (PFS).

Main Results:

• Of 71 patients retreated with EGFR-TKIs, 7% had partial response (PR), 36.6% stable disease (SD), and 56.3% progressive disease (PD).
• The overall disease control rate (DCR) was 43.7%.
• Factors associated with good PFS upon retreatment included Exon 21 mutation, initial PFS ≥ 6 months, and an interval of ≥ 3 months between treatments.

Conclusions:

• Retreatment with EGFR-TKIs may be a viable option for selected NSCLC patients.
• Positive outcomes are associated with active Exon 21 mutations, favorable initial PFS (≥ 6 months), and a treatment-free interval of at least 3 months.